| Name | Title | Contact Details |
|---|
USMD is a publicly held (NASDAQ: USMD), physician-led integrated healthcare system committed to exemplary patient care. Headquartered in Irving, Texas, USMD serves the Dallas-Fort Worth metropolitan area with more than 250 physicians and associate practitioners, and provides healthcare services to patients in just under 20 different specialties at its hospitals, nine cancer treatment centers and nearly 70 physician clinics. For more information about USMD, visit www.usmd.com.
Clear skin can be life-changing, but it`s not easy to see a dermatologist. At Curology, we provide prescription medications custom-formulated for each patient`s skin and shipped directly to their door. We tailor the entire Curology experience specifically for patients with acne and anti-aging concerns, allowing us to provide incredibly personalized, effective and affordable care at scale. We`ve assembled a committed team of dermatology providers and created a secure online platform, bringing professional acne care and prescription treatment to tens of thousands of people who wouldn`t otherwise be able to access or afford it. Curology helps people see tremendous, long-term improvements previously accessible only to a small percentage of the population. Our formulas are already on tens of thousands of sinks across the US. Our technology enables 1:1 chats with real dermatology providers and lets users to share their journeys with an engaged and growing community. Members can upload photos and track their progress over SMS, as well as browse and post digital postcards to share victories and encourage others. Curology is headquartered in the beautiful Hayes Valley neighborhood of San Francisco.
Croes Communications, Inc is a Oak Hall, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Anamed Inc. is a Lake Forest, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.